Achillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 a...
August 11 2016 - 6:05AM
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
announced today that interim results from an ongoing phase 2a
clinical trial, being conducted by Alios BioPharma Inc., part of
the Janssen Pharmaceutical Companies of Johnson & Johnson
(Janssen), to evaluate all-oral combination regimens, containing
odalasvir, AL-335 and simeprevir, were accepted for presentation at
the EASL – American Association for the Study of Liver Diseases
(AASLD) Special Conference: New Perspectives in Hepatitis C Virus
Infection – The Roadmap for Cure, being hosted in Paris, France on
September 23 – 24, 2016.
The eposter, entitled “Short duration treatment
with AL-335 and odalasvir (ODV), with or without simeprevir (SMV),
in treatment naïve patients with hepatitis C virus (HCV) genotype
(GT) 1 infection,” will be presented on Friday, September 23,
2016.
This phase 2a study aims to establish the safety,
pharmacokinetics and efficacy of doublet and triplet regimens,
consisting of odalasvir and AL-335 with or without simeprevir, in
treatment naïve patients with genotype 1 HCV infection for
treatment durations of eight weeks or less. Further information
about this study can be found at www.clinicaltrials.gov. Study
identifier: NCT02569710.
About HCV
The hepatitis C virus (HCV) is one of the most
common causes of viral hepatitis, which is an inflammation of the
liver. It is currently estimated that more than 150 million people
are infected with HCV worldwide including approximately 5 million
people in the United States. Three-quarters of the HCV patient
population is undiagnosed; it is a silent epidemic and a major
global health threat. Chronic hepatitis, if left untreated, can
lead to permanent liver damage that can result in the development
of liver cancer, liver failure or death. Despite available
treatments, there remains a significant unmet need for many
patients infected with HCV.
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a
science-driven, patient-focused company seeking to leverage its
strengths across the continuum from discovery to commercialization
in its goal of providing better treatments for people with serious
diseases. The company seeks to employ a highly-disciplined
discovery and development approach that has allowed it to pursue
best-in-class oral antiviral therapy for chronic hepatitis C (HCV)
and build a platform of potent and specific complement inhibitors.
Achillion is rapidly advancing its efforts to become a
fully-integrated pharmaceutical company with a goal of bringing
life-saving medicines to patients with rare diseases. More
information is available at http://www.achillion.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release includes forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that are subject to risks, uncertainties and
other important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements.
Achillion may use words such as “expect,” “anticipate,” “project,”
“intend,” “plan,” “aim,” “believe,” “seek,” “ estimate,” “can,”
“focus,” “will,” “look forward,” “goal,” and “may” and similar
expressions to identify such forward-looking statements. These
forward-looking statements also include statements about: the
Company’s expected plans, timing, data readouts and results from
ongoing and planned clinical trials of HCV development candidates
being advanced by Janssen under the Company’s collaboration with
Janssen; and statements concerning the Company’s strategic goals,
milestone plans, and prospects. Among the important factors that
could cause actual results to differ materially from those
indicated by such forward-looking statements are risks relating to,
among other things Achillion’s ability to: obtain and maintain
patent protection for its drug candidates and the freedom to
operate under third party intellectual property; demonstrate in any
current and future clinical trials the requisite safety, efficacy
and combinability of its drug candidates; obtain and maintain
necessary regulatory approvals; identify, enter into and maintain
collaboration agreements with third-parties, including the current
collaboration with Janssen; compete successfully in the markets in
which it seeks to develop and commercialize its product candidates
and future products; manage expenses; manage litigation; raise the
substantial additional capital needed to achieve its business
objectives; and successfully execute on its business strategies.
Furthermore, because Janssen is solely responsible for the
development and commercialization of our HCV assets under the
exclusive worldwide license we granted to it and has the deciding
vote on all collaboration matters, Janssen generally has full
discretion over all development plans and strategies and may not
advance the HCV programs in the time frames Achillion or Janssen
projects, or at all, including with regard to the current and
planned phase 2a and phase 2b combination trials that include our
licensed drug candidates. These and other risks are described in
the reports filed by Achillion with the U.S. Securities and
Exchange Commission, including its Quarterly Report on Form 10-Q
for the fiscal quarter ended June 30, 2016, and its subsequent SEC
filings.
In addition, any forward-looking statement in this
press release represents Achillion’s views only as of the date of
this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Investors:
Glenn Schulman
Achillion Pharmaceuticals, Inc.
Tel. (203) 752-5510
gschulman@achillion.com
Media:
Liz Power
Achillion Pharmaceuticals, Inc.
Tel: (203) 752-5509
lpower@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024